📰 Andy Plump News
Page 2 - Andy Plump News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Andy Plump. Real-time updates on events, politics, business and more.
May 16, 2023
Christopher O’Reilly: Thank you very much for joining FY 2022 earnings announcement of Takeda. I will serve as MC, Head of IR. My name is O’Reilly.
March 20, 2023
Takeda Pharmaceutical drug TAK-279 achieved the main goal of a mid-stage clinical trial in plaque psoriasis, setting the stage for Phase 3. The Japanese pharmaceutical giant sees the small molecule as complementary to its top-selling product, the blockbuster inflammatory bowel disorder drug Entyvio, and competitive against Bristol Myers Squibb's Sotyktu.
February 3, 2023
Christopher OReilly: Thank you for taking time out of your very busy schedule to join us for the FY 22 Q3 Earnings Announcement by Takeda. My name is OReilly, Head of IR.
December 14, 2022
Japan: Takeda has announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment...
December 13, 2022
13.12.2022 - Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases ...
October 28, 2021
Over a year into a stunning FDA warning letter, Takeda has resolved manufacturing problems at home as it gears up to make Novavax’s COVID-19 vaccine for Japan.